Adaptive Biotechnologies Corp. (ADPT)

In the past six months, Adaptive Biotechnologies' stock has experienced significant positive momentum, with shares up 250% in the past year and hitting a new three-year high in October 2025. In Q1 2025, the company reported strong MRD revenue growth and raised its full-year revenue guidance. In Q2 2025, Adaptive Biotechnologies reported total revenue growth, with the MRD business achieving positive adjusted EBITDA, and the company again raised its full-year MRD revenue guidance. Several research firms issued positive reports and raised their price objectives for the company's stock. ARK Invest continued to divest shares of Adaptive Biotechnologies.

Based on the available information, there is no explicit mention of demand seasonality for Adaptive Biotechnologies' products and services. The company has reported consistent growth in clonoSEQ test volumes and the MRD business, suggesting a relatively stable or growing demand rather than significant seasonal fluctuations.

Adaptive Biotechnologies Corp. is a commercial-stage biotechnology company focused on leveraging the adaptive immune system to transform disease diagnosis and treatment. The company operates within the Healthcare sector, specifically in the Biotechnology industry, encompassing Biological Products, Clinical Diagnostics Devices, and Biotechnology & Medical Research. Its core business revolves around its proprietary immune medicine platform, which decodes the genetic information of T-cell and B-cell receptors to understand immune responses to disease. Its major products and services include clonoSEQ, an FDA-cleared diagnostic test; immunoSEQ, a research-use-only service; and cellular therapy and vaccines.

Adaptive Biotechnologies is headquartered in Seattle, Washington, and maintains research and operations facilities across North America and Europe.

Adaptive Biotechnologies appears to have a strong and positive brand reputation, reflected through favorable market sentiment and analyst confidence. The stock's significant appreciation and the consensus "Moderate Buy" rating from analysts indicate a positive perception of the company's prospects and technology. Barchart also maintains a 100% "Buy" opinion for ADPT. The company's consistent revenue growth and achieving profitability in its MRD segment contribute to a positive market view.

Institutional investors and hedge funds collectively own a significant portion of Adaptive Biotechnologies' stock, accounting for 99.17% of the outstanding shares. Allianz Asset Management GmbH increased holdings by 519.5% in Q2 2025. Russell Investments Group Ltd. boosted its position by 104.7% in Q1 2025. GAMMA Investing LLC grew holdings by 36.5% in Q1 2025. Wealth Enhancement Advisory Services LLC, Diversified Trust Co, Peregrine Capital Management LLC, University of Texas Texas AM Investment Management Co., and Blair William & Co. IL acquired new stakes in Q1 and Q2 2025. The co-founders are Chad Robins (CEO) and Harlan Robins (Chief Scientific Officer).